WoS İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6
Browse
4 results
Search Results
Article Prevalence of Fecal Incontinence After Childbirth in Turkey: Systematic Review and Meta-Analysis(Springer London Ltd, 2025) Kaya, Husniye Dinc; Gunaydin, Sevil; Kilic, Melek; Ozdemir, Iclal IlknurBackgroundFecal incontinence (FI), defined as the reduced or lost ability to control the elimination of solid or liquid stool and gas due to anal sphincter dysfunction, is mostly caused by childbirth.AimThis study aimed to determine the prevalence of postpartum fecal incontinence in Turkey.MethodsThis systematic review and meta-analysis were conducted between December 1 and December 31, 2024, considering inclusion and exclusion criteria. The literature search was performed using PubMed, Science Direct, Medline, Ovid, Ebsco CINAHL Plus, and Cochrane Library databases. The methodological quality of the included studies was assessed using the checklist developed by the Joanna Briggs Institute.ResultsA total of six studies were included in this review. The combined results indicated that the prevalence of postpartum fecal incontinence in Turkey is approximately 3%. Women who delivered by cesarean section had significantly lower rates of FI than those who delivered vaginally (z = 3.10, p = 0.002, CI: 0.39 [0.21, 0.71]). Additionally, the combined results of the studies showed no significant relationship between fecal incontinence and menopausal status, indicating that premenopausal and postmenopausal women had similar rates of fecal incontinence (z = 0.02, p = 0.98, CI: 0.97 [0.10, 9.47]).ConclusionFecal incontinence can occur after childbirth. The postpartum fecal incontinence rate in Turkey is 3%, and it is associated with the mode of delivery but not with menopausal status. A thorough postpartum examination is recommended for the early detection of fecal incontinence.PROSPERO Registration No: CRD420250653603.ConclusionFecal incontinence can occur after childbirth. The postpartum fecal incontinence rate in Turkey is 3%, and it is associated with the mode of delivery but not with menopausal status. A thorough postpartum examination is recommended for the early detection of fecal incontinence.PROSPERO Registration No: CRD420250653603.Article Citation - WoS: 22Citation - Scopus: 22The Earthquakes in Turkey and Their Effects on Nursing and Community Health(Wiley, 2023) Seren, Arzu Kader Harmanci; Dikec, Guel; Harmanci Seren, Arzu KaderBackgroundSevere damage was experienced in 10 provinces in Turkey, and the north of Syria, with the earthquakes that hit Kahramanmaras at midnight and afternoon on February 6, 2023. AimThe authors aimed to give brief information to the international nursing community about the situation related to earthquakes in the aspects of nurses. ConclusionThese earthquakes caused traumatic processes in the affected regions. Many people, including nurses and other healthcare professionals, died or were injured. The results demonstrated that the required preparedness had not been applied. Nurses went to these areas voluntarily or on assignment and cared for individuals with injured. The universities in the country passed to distance education because of the shortage of safe places for victims. This situation also negatively influenced nursing education and clinical practice by interrupting in-person education one more time after the COVID-19 pandemic. Implications for nursing and nursing policySince the outcomes show a need for well-organized health and nursing care, policymakers may consider getting nurses' contributions to the disaster preparedness and management policy-making processes.Review Citation - WoS: 3Citation - Scopus: 3Age-Specific Seroprevalence of Hepatitis a Virus in Turkey Between 2000 and 2023: Systematic Review and Meta-Analysis(Mdpi, 2024) Ciftci, Ihsan Hakki; Koroglu, Mehmet; Demiray, Tayfur; Terzi, Huseyin Agah; Kilbas, Elmas Pinar Kahraman; Kahraman Kilbas, Elmas Pinar<bold>Background</bold>: Hepatitis A virus (HAV) is a leading cause of acute viral hepatitis and is primarily transmitted by the fecal-oral route. The clinical presentation and progression of the disease varies according to the age of the patient. Turkey is classified as a moderately endemic country, and HAV infection continues to be an important public health problem worldwide. <bold>Methods</bold>: In this study, a systematic meta-analysis was conducted to evaluate age-specific HAV seroprevalence rates in Turkey between 2000 and 2023. A comprehensive literature review identified 57 articles that met the inclusion criteria. The studies were assessed for quality, and seroprevalence rates were evaluated across four different age groups. Statistical analyses were performed using Comprehensive Meta-Analysis (CMA) software (CMAVersion 3.0) and SPSS (SPSS Statistics 25.0). <bold>Results</bold>: HAV seroprevalence rates were found to be 73.18% in the 0 < 5 age group and 90.90% in the >35 age group. The overall seroprevalence estimated using a random effects model was 64.5% (95% CI: 58.3-70). High heterogeneity was observed among the studies, and the prevalence estimates changed when low-quality studies were excluded. <bold>Conclusions</bold>: This meta-analysis suggests that the increasing trend in HAV IgG seroprevalence in Turkey, especially among young populations, is likely due to the vaccination program initiated in 2012. Furthermore, the heterogeneity observed among regions highlights the importance of regional public health strategies. Future studies should focus on providing more detailed data to evaluate the long-term effects of vaccination and to explain regional differences in HAV seroprevalence.<br />Article Citation - WoS: 3Citation - Scopus: 2Hepatitis B Immunization Data of Patients Living With Hiv/Aids: a Multi-Centre Study(Natl inst Public Health, 2022) Ozturk, Servet; Ozel, Ayse Serra; Ergen, Pinar; Senbayrak, Seniha; Agalar, CananObjectives: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are the two leading viruses that cause the greatest number of virus-related morbidities in the world. HIV/HBV coinfection is correlated with high morbidity and mortality. For this particular reason hepatitis B vaccination is crucial for people living with HIV. Methods: Patients who are being followed-up for HIV/AIDS and who have received a hepatitis B vaccine in 4 HIV clinics over a 5-year time period have been studied. Our multi-centered, retrospective, cross-sectional and observational study investigates factors that affect hepatitis B vaccination immune response of individuals living with HIV. The patients have been studied for the parameters such as age, sex, CD4 count at the time of diagnosis or vaccination, HIV-RNA levels, comorbidities, vaccine dosage, success of immunization after vaccination, and the demographics of the patients who have and have not developed immunity. Results: Of 645 patients that are being followed-up in our clinics, 158 received hepatitis B vaccine; 39 of these 158 patients have been excluded from the study because they did not fulfil the inclusion criteria. Finally, 119 patients were evaluated in the study, 17 of the patients (14.3%) were females and 102 (85.7%) were males. The median age was 41.11 +/- 10.09 (min-max: 18-75). Twenty-three of the patients (19.3%) were at the stage of AIDS during diagnosis while 80.7% were at the stage of HIV infection. Ninety-one of the patients (76.5%) have been administered a single dose hepatitis B vaccine on the standard 0, 1st, 6th month vaccination schedule, whereas 23.5% were administered a double dose on the same vaccination schedule. When further evaluated to find whether the patient was able to develop sufficient immunity (anti-HBs >= 10), it was found that the immune response was statistically significantly higher in the patients whose CD4 count was greater than 200 at the time of the first diagnosis and vaccination (p = 0.05 and p = 0.001, respectively). The patients have also been evaluated according to the number of doses they received (1 vs. 2). The immune response of the patients who received two doses was statistically significantly higher (p = 0.041). Conclusion: We can conclude that in the patients with CD4 count less than 200 at the time of their diagnosis and vaccination a high dose recombinant hepatitis B vaccine should definitely be administered as the normal dose and higher dose have similar side effect profiles and the higher dose provides greater immunity.